Skip to main content
Shanghai Hile Bio-Technology Co.,Ltd logo

Shanghai Hile Bio-Technology Co.,Ltd — Investor Relations & Filings

Ticker · 603718 ISIN · CNE1000022T4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,480 across all filing types
Latest filing 2025-04-21 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603718

About Shanghai Hile Bio-Technology Co.,Ltd

http://www.hile-bio.com/

Shanghai Hile Bio-Technology Co., Ltd. specializes in the research, development, production, and distribution of veterinary biological products. The company focuses on providing comprehensive health solutions for the livestock and poultry sectors. Its core product portfolio includes a wide range of vaccines targeting major animal diseases, such as swine fever, porcine reproductive and respiratory syndrome (PRRS), foot-and-mouth disease, and various avian influenza strains. Utilizing advanced biotechnology and large-scale manufacturing processes, the company operates high-standard production facilities compliant with Good Manufacturing Practice (GMP) requirements. Hile Bio-Technology emphasizes innovation through its dedicated research and development centers, aiming to enhance animal disease prevention and control. The company serves large-scale farming enterprises and veterinary service providers, maintaining a significant presence in the animal health sector through its commitment to product quality and technical support.

Recent filings

Filing Released Lang Actions
海利生物内部控制审计报告书（中兴华内控审计字【2025】第430007号）
Regulatory Filings
2025-04-21 Chinese
海利生物关于会计政策变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Haili Biotechnology Co., Ltd. regarding a change in accounting policies based on new accounting guidelines issued by the Ministry of Finance in 2024. It details the nature of the accounting policy change, the reasons for the change, and the impact on the company's financial statements. The document is relatively short (1276 characters) and serves as a formal notification of the accounting policy change rather than a full financial report or audit report. It does not contain comprehensive financial statements or detailed audit results. Therefore, it is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements that do not fit other specific categories.
2025-04-21 Chinese
申港证券股份有限公司关于海利生物重大资产购买及重大资产出售之2024年度业绩承诺完成情况的核查意见
Regulatory Filings
2025-04-21 Chinese
海利生物董事会关于独立董事独立性情况的专项意见
Governance Information Classification · 95% confidence The document is a special opinion from the board of directors regarding the independence of the company's independent directors. It references regulatory rules about independent directors and confirms their independence status. There is no financial data, no report attached or announced, and no mention of a meeting or voting results. This is a governance-related disclosure about board members' independence, fitting best under Governance Information (CGR). The document is short and focused solely on governance compliance.
2025-04-21 Chinese
海利生物2024年年度报告
Annual Report Classification · 100% confidence The document is titled "上海海利生物技术股份有限公司2024 年年度报告" which translates to "Shanghai Hile Biotechnology Co., Ltd. 2024 Annual Report." It contains detailed sections typical of an annual report, including company overview, financial data for the year 2024, management discussion and analysis, governance, environmental and social responsibility, and audited financial statements. The document references the audit report by an accounting firm and includes comprehensive financial figures, business performance, and future outlook. The length is substantial (15,000 characters), and it is not merely an announcement or a certification. Therefore, this document is the official Annual Report for the fiscal year 2024. FY 2024
2025-04-21 Chinese
海利生物2024年度对会计师事务所履职情况的评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm for the year 2024, specifically assessing the audit work done by the accounting firm for the company's 2024 financial statements and internal controls. It references audit standards, audit procedures, and the issuance of an unqualified audit opinion. The document is not the audit report itself but an evaluation of the auditor's performance and independence. It does not contain actual financial statements or detailed financial data. The document length is 2385 characters, which is relatively short and consistent with an evaluation or assessment report rather than a full audit report. Therefore, this document fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related information about audit performance and procedures, excluding full annual reports. FY 2024
2025-04-21 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.